cytarabine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beppu, H; Mizutani, K; Nagao, S; Orand, A; Sonoda, S; Suzuki, S; Takahashi, H; Takayanagi, N; Tomita, Y | 1 |
| Andersson, A; Dannaeus, K; Delfani, K; Di Monte, DA; Haegerstrand, A; Häggblad, J; Hill, MP; Isacson, R; Janson Lang, AM; McCormack, AL; Nielsen, E; Palmer, T; Patrone, C; Rönnholm, H; Wikstrom, L; Zachrisson, O; Zhao, M | 1 |
2 other study(ies) available for cytarabine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Pelvic axis-based gait analysis for ataxic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antimetabolites, Antineoplastic; Ataxia; Biomechanical Phenomena; Cytarabine; Diet; Dopamine Agents; Gait; Hindlimb; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Pelvis; Video Recording | 2013 |
Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiogenesis Inducing Agents; Animals; Becaplermin; Cell Proliferation; Cytarabine; Disease Models, Animal; Drug Administration Schedule; Immunosuppressive Agents; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurotoxins; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-sis; Rats; Rats, Sprague-Dawley; Time Factors | 2011 |